To provide services for Bioavailability/Bioequivalence (BA/BE) of all pharmaceutical products including oral to intravenous with single or double API.
Particularly cost-effective drug development, drug testing, BA/BE studies (IRB/EC approved, ICH/GCP compliant quality controlled and quality assured studies)
Need of IBBPS
Dow University of Health Sciences (DUHS) has fulfilled the need for facilities to study BA/BE of drugs due to the following requirements in Pakistan.
Pakistan exports drugs worth US $ 200 million per year and these exports may increase further by carrying out BA/BE studies within the country saving also in the expenditure in foreign exchange for these studies abroad by Pakistani pharmaceutical companies. BA/BE study will help the local pharmaceuticals industries to expand their business in any other country that will lead to increase the sale of products.
World Health Organization (WHO) requires BA/BE studies for procurement of medical products
BA/BE studies will give confidence to health care providers on the quality of drug products.
BA/BE studies will also give the choice to the Consumer for purchasing a quality product among the different available brands in cheap rates.
There is a need to develop more Bioequivalence centers in Pakistan for conducting equivalent studies and give the society quality medicines and decrease the mortality level due to the usage of spurious or adulterated drug products.
